Aloxi® (palonosetron hydrochloride) injection

Aloxi® (palonosetron hydrochloride) Injection is a potent, highly selective 5-HT₃ receptor antagonist developed for the prevention of chemotherapy-induced nausea and vomiting (CINV). Aloxi is the first 5-HT₃ receptor antagonist to be indicated for the prevention of both acute and delayed CINV.

Dacogen® (decitabine) for Injection

Dacogen® (decitabine) for Injection is indicated for treatment of patients with myelodysplastic syndromes (MDS), including previously treated and untreated, de novo, and secondary MDS of all FAB subtypes (RA, RARS, RAEB, RAEB-t, CMML) and Intermediate-1 and Intermediate-2, and High Risk IPSS groups.

Full Prescribing Information (PDF)

GLIADEL® Wafer (polifeprosan 20 with carmustine implant)

Gliadel® Wafer (polifeprosan 20 with carmustine implant) is a biodegradable wafer containing the chemotherapy agent carmustine, or BCNU, approved for the treatment of high grade malignant gliomas as an adjunct to surgery and radiation. As Gliadel dissolves, BCNU provides site-specific chemotherapy.

Hexalen® (altretamine) Capsules

Hexalen® (altretamine) Capsules are an orally administered chemotherapeutic agent for the treatment of refractory ovarian cancer. Hexalen is a medically important product that has induced complete responses in patients refractory to first-line therapy.

Salagen® (pilocarpine hydrochloride) Tablets

Salagen® (pilocarpine hydrochloride) Tablets are an important product for the management of xerostomia, or dry mouth symptoms, associated with head and neck cancer radiation and Sjögren's syndrome.

Full Prescribing Information (PDF)

For patient assistance and help with reimbursement questions regarding MGI PHARMA, INC.'s marketed products, please contact the MGI PHARMA Access Program (MAP) at 1-877-644-6270.